SCHEDULE 13G: Opaleye Management Discloses 6.17% Beneficial Ownership in Larimar Therapeutics
Beneficial Ownership Report
Opaleye Management, Inc., along with Opaleye, L.P. and James Silverman, has reported a 6.17% beneficial ownership stake in Larimar Therapeutics, Inc. common stock.
Summary
- Opaleye Management, Inc., Opaleye, L.P., and James Silverman have jointly filed a Schedule 13G, disclosing their beneficial ownership in Larimar Therapeutics, Inc.
- The reporting persons collectively beneficially own 3,952,409 shares of Larimar Therapeutics, Inc. Common Stock.
- This ownership represents 6.17% of the total outstanding shares of the class.
- The shares are held with shared voting power and shared dispositive power, meaning decisions regarding these shares are made jointly by the reporting entities.
- The filing indicates that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: Neutral, as this is a factual disclosure of beneficial ownership and does not contain performance or forward-looking statements, nor does it imply any specific positive or negative operational developments for the company.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant ownership stake by an institutional investor in a publicly traded company, common in the financial industry. It does not provide specific insights into broader industry trends or competitive positioning beyond the investment itself.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may be viewed positively by some investors as a vote of confidence, while others may analyze the potential for future influence or changes in ownership structure.
Key Dates
| Date | Description |
|---|---|
| 04/09/2025 | Date of event which requires the filing of this statement |
| 04/16/2025 | Date of filing of this statement |
Keywords
Larimar Therapeutics, Opaleye Management, Opaleye L.P., James Silverman, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Equity Stake, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.